278 related articles for article (PubMed ID: 33335279)
21. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
22. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
23. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
[TBL] [Abstract][Full Text] [Related]
24. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma.
Ebata A; Suzuki T; Takagi K; Miki Y; Onodera Y; Nakamura Y; Fujishima F; Ishida K; Watanabe M; Tamaki K; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2012 Aug; 19(4):485-96. PubMed ID: 22569827
[TBL] [Abstract][Full Text] [Related]
25. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
26. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
27. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract][Full Text] [Related]
28. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
[TBL] [Abstract][Full Text] [Related]
29. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
30. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
[TBL] [Abstract][Full Text] [Related]
31. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
33. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer.
Wang L; Lyu S; Wang S; Shen H; Niu F; Liu X; Liu J; Niu Y
Exp Mol Pathol; 2016 Feb; 100(1):177-83. PubMed ID: 26721716
[TBL] [Abstract][Full Text] [Related]
34. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
[TBL] [Abstract][Full Text] [Related]
35. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
[TBL] [Abstract][Full Text] [Related]
36. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K; Masuda N; Hayashi N; Sagara Y; Hara F; Kadoya T; Matsui A; Miyazaki C; Shien T; Tokunaga E; Hayashi T; Niikura N; Maeda S; Komoike Y; Bando H; Kanbayashi C; Iwata H
Breast Cancer; 2021 Jul; 28(4):896-903. PubMed ID: 33599914
[TBL] [Abstract][Full Text] [Related]
38. 14-3-3ζ promoted invasion and lymph node metastasis of breast invasive ductal carcinoma with HER2 overexpression.
Wan D; Zhang Y; Yu Q; Li F; Zhuo J
Pathol Res Pract; 2021 Nov; 227():153619. PubMed ID: 34560418
[TBL] [Abstract][Full Text] [Related]
39. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]